OPALESCENCE : 89 Zr TLX250 Immuno-PET Cohort

Essais cliniquesType of study : Single-centre study

Pathology : Metastatic triple negative breast cancer

Principal investigator : Dr. Caroline Rousseau

NCT number : NCT04758780



Numerous clinical studies have shown the prognostic value of CAIX expression in breast cancer patients: high CAIX expression correlates with a poor prognosis.

The aim of this study is to evaluate the concordance for tumour lesion detection of 89Zr-TLX250 (CAIX marker) PET/CT imaging and conventional (CT) and FDG PET/CT imaging on a per lesion basis.



Logo SIRIC ILIAD Nantes AngersLogo ICO


Recommended Posts